<i>Bifidobacterium</i> alleviate metabolic disorders via converting methionine to 5’-methylthioadenosine
Qiang Lyu, Rou-An Chen, Hsiao-Li Chuang, Hsin-Bai Zou, Lihong Liu, Li‐Kang Sung, Po‐Yu Liu, Hsin‐Yi Wu, Hsin-Yuan Chang, Wan‐Ju Cheng, Wei‐Kai Wu, Ming‐Shiang Wu, Cheng‐Chih Hsu
Abstract
Dietary patterns and corresponding gut microbiota profiles are associated with various health conditions. A diet rich in polyphenols, primarily plant-based, has been shown to promote the growth of probiotic bacteria in the gastrointestinal tract, subsequently reducing the risk of metabolic disorders in the host. The beneficial effects of these bacteria are largely due to the specific metabolites they produce, such as short-chain fatty acids and membrane proteins. In this study, we employed a metabolomics-guided bioactive metabolite identification platform that included bioactivity testing using in vitro and in vivo assays to discover a bioactive metabolite produced from probiotic bacteria. Through this approach, we identified 5’-methylthioadenosine (MTA) as a probiotic bacterial-derived metabolite with anti-obesity properties. Furthermore, our findings indicate that MTA administration has several regulatory impacts on liver functions, including modulating fatty acid synthesis and glucose metabolism. The present study elucidates the intricate interplay between dietary habits, gut microbiota, and their resultant metabolites.